Rachel K. King - Dec 31, 2022 Form 5 Insider Report for GLYCOMIMETICS INC (GLYC)

Role
Director
Signature
/s/ Brian F. Leaf, attorney-in-fact
Stock symbol
GLYC
Transactions as of
Dec 31, 2022
Transactions value $
$0
Form type
5
Date filed
2/6/2023, 03:13 PM
Previous filing
Jun 21, 2022
Next filing
Apr 2, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GLYC Common Stock Will/Inheritance $0 +11.6K +2.38% $0.00 501K Feb 15, 2022 Direct F1, F2
transaction GLYC Common Stock Will/Inheritance $0 +7.5K $0.00 7.5K Aug 2, 2022 By RBK LLC F3
holding GLYC Common Stock 92.4K Dec 31, 2022 By trusts F4
holding GLYC Common Stock 45.7K Dec 31, 2022 By spouse
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 48,125 shares underlying restricted stock units held as of the date of this report. Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
F2 This total also includes 37,000 shares previously held by The Rachel K. King 2016 GRAT that were transferred to the reporting person on February 25, 2021 and are now owned directly by the reporting person.
F3 The reporting person is co-manager of this entity. She disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein.
F4 These shares are held by family trusts, for which Ms. King serves as trustee, as follows: 1,741 shares are held by The Connor A. King 1988 Trust, 1,741 shares are held by The Langley C. King 1990 Trust, 8,796 shares are held by the 1995 Connor A. King Trust, 8,796 shares are held by the 1995 Langley C. King Trust, 23,301 shares are held by The Connor King 2013 GRAT, 23,301 shares are held by The Langley C. King 2013 GRAT and 24,725 shares are held by The Rachel K. King 2016 GRAT. The number of shares held by The Rachel K. King 2016 GRAT excludes the 37,000 shares transferred to the reporting person as described in footnote 2.